Cathepsin B Protein (Ctsb) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. PMID: 40385417
Overview
This page provides comprehensive information about Cathepsin B Protein, including its structure, normal function in the nervous system, and its role in neurodegenerative diseases. PMID: 38903897
Cathepsin B Protein (Ctsb) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. PMID: 40385417
Overview
This page provides comprehensive information about Cathepsin B Protein, including its structure, normal function in the nervous system, and its role in neurodegenerative diseases. PMID: 38903897
Cathepsin B is a lysosomal cysteine protease with unique features: PMID: 27333827
Signal peptide (aa 1-17): Directs entry into the secretory pathway
Propeptide (aa 18-62): Inhibits activity until processed in lysosomes
Heavy chain (aa 63-252): Contains the catalytic cleft with Cys29, His199, and Asn219
Light chain (aa 253-331): Stabilizes the enzyme structure
Cathepsin B is unique among cathepsins because it has occluding loop that gives it both endopeptidase and exopeptidase (dipeptidyl carboxypeptidase) activity. PMID: 12677446
Expression Pattern
Cathepsin B exhibits widespread expression across multiple tissue types:
Brain: Expressed in [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), and [microglia](/entities/microglia) throughout the CNS
Highest expression: Liver, kidney, and spleen
Cellular localization: Primarily lysosomal, with some secreted forms
Regulation: Upregulated under inflammatory conditions and during cellular stress
[Blood-brain barrier](/entities/blood-brain-barrier): Can be secreted and cross BBB under pathological conditions
Normal Function
Cathepsin B has important physiological roles:
Protein Degradation: Major lysosomal protease that degrades proteins, including extracellular matrix components
Antigen Processing: Processes antigens for MHC class II presentation in antigen-presenting cells
[Apoptosis](/mechanisms/apoptosis) Regulation: Can activate or inhibit apoptotic pathways depending on context
Extracellular Remodeling: Under certain conditions, secreted cathepsin B degrades ECM and basement membrane components
Hormone Processing: Activates prohormones in the secretory pathway
Immune Response: Modulates inflammasome activation and cytokine release
Role in Disease
Alzheimer's Disease
Cathepsin B is implicated in AD pathogenesis:
[Aβ](/proteins/amyloid-beta) Processing: Can cleave [APP](/entities/app-protein) and generate [Aβ](/proteins/amyloid-beta) peptides through non-amyloidogenic pathways
Inflammation: Released from activated [microglia](/cell-types/microglia), contributing to chronic neuroinflammation
Neuronal Death: Lysosomal membrane permeabilization leads to cathepsin B release and [apoptosis](/entities/apoptosis)
Therapeutic Target: Cathepsin B inhibitors are being explored as AD therapeutics
Parkinson's Disease
[α-Synuclein](/proteins/alpha-synuclein) Degradation: Can degrade α-synuclein, but may also generate aggregation-prone fragments
Dopaminergic Neuron Vulnerability: Elevated cathepsin B expression in PD substantia nigra
Lysosomal Dysfunction: Implicated in PD-related lysosomal storage disorders like Gaucher disease
Mitochondrial Quality Control: Involved in mitophagy and mitochondrial dysfunction
Other Neurodegenerative Diseases
Amyotrophic Lateral Sclerosis (ALS): Elevated in motor neurons and glia
Huntington's Disease (HD): Mutant [huntingtin](/proteins/huntingtin-protein) affects lysosomal function and cathepsin B activity
Multiple System Atrophy (MSA): Implicated in oligodendrocyte dysfunction
Cancer and Metastasis
ECM Degradation: Promotes tumor invasion and metastasis
Angiogenesis: Supports new blood vessel formation in tumors
Therapeutic Target: Cathepsin B inhibitors in cancer clinical trials
Molecular Mechanisms
Catalytic Mechanism
Cathepsin B uses a cysteine protease mechanism:
Nucleophile: Cys29 in the catalytic dyad
Acid/Base: His199 facilitates proton transfer
Asn219: Stabilizes the oxyanion hole
Optimal pH: 5.5-6.5 in lysosomal environment
Substrate Specificity
Prefers basic residues (Arg, Lys) at P2 position
Peptidyl diphenyl phosphonates are potent inhibitors
Activity modulated by glycosylation and phosphorylation
Therapeutic Targeting
Challenges
Achieving brain penetration with small molecule inhibitors
Maintaining sufficient therapeutic window
Avoiding interference with normal lysosomal function
Animal Models
Ctsb knockout mice: Viable with minimal phenotype, altered autophagic flux
Transgenic models: APP/PS1 mice with Ctsb deletion show reduced amyloid plaques
AAV models: Overexpression of human CTSB in mouse brain increases neurodegeneration
Research Directions
Biomarker Development: Cathepsin B activity in CSF as neurodegenerative disease biomarker
Blood-Brain Barrier Penetrance: Developing brain-penetrant cathepsin B inhibitors
Combination Therapies: Targeting cathepsin B alongside other proteases
Personalized Medicine: Genetic variants affecting cathepsin B activity and drug response
Key Publications
Yan S, et al. (2020) "Cathepsin B and Alzheimer's disease." Adv Exp Med Biol 1235:85-104. [DOI:10.1007/978-3-030-41679-9_4](https://doi.org/10.1007/978-3-030-41679-9_4)
Hook G, et al. (2014) "Cathepsin B in neurodegeneration of Alzheimer's disease." Curr Alzheimer Res 11:654-664.
Vidak E, et al. (2019) "Cathepsin B: A potential therapeutic target in neurodegeneration." J Neurochem 150:501-517. [DOI:10.1111/jnc.14818](https://doi.org/10.1111/jnc.14818)
Benes P, et al. (2008) "Cathepsin B: multiple functions in cancer." Neoplasma 55:253-264.
Hook V, et al. (2021) "Cathepsin B: therapeutic target for neurodegenerative diseases." Nat Rev Drug Discov 20:33-48.
Background
The study of Cathepsin B Protein (Ctsb) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.